Identification and characterization of two DMD pedigrees with large inversion mutations based on a long-read sequencing pipeline.
Chang GengCiliu ZhangPidong LiYuanren TongBaosheng ZhuJing HeYanhuan ZhaoFengxia YaoLi-Ying CuiFan YangYang WangYaru WangHongshuai JinDandan LangShanlin LiuDepeng WangMin S ParkLin ChenJing PengYi DaiPublished in: European journal of human genetics : EJHG (2022)
Pathogenic large inversions are rarely reported on DMD gene due to the lack of effective detection methods. Here we report two DMD pedigrees and proposed a reliable pipeline to define large inversions in DMD patients. In the first pedigree, conventional approaches including multiplex ligation-dependent probe amplification, and whole-exome sequencing by next generation sequencing were failed to detect any pathologic variant. Then an advanced analysis pipeline which consists of RNA-seq, cDNA array capture sequencing, optical mapping, long-read sequencing was built. RNA-seq and cDNA capture sequencing showed a complete absence of transcripts of exons 3-55. Optical mapping identified a 55 Mb pericentric inversion between Xp21 and Xq21. Subsequently, long-read sequencing and Sanger sequencing determined the inversion breakpoints at 32,915,769 and 87,989,324 of the X chromosomes. In the second pedigree, long-read sequencing was directly conducted and Sanger sequencing was performed to verify the mutation. Long-read sequencing and Sanger sequencing found breakpoints at 32,581,576 and 127,797,236 on DMD gene directly. In conclusion, large inversion might be a rare but important mutation type in DMD gene. An effective pipeline was built in detecting large inversion mutations based on long-read sequencing platforms.
Keyphrases
- radiation therapy
- single cell
- rna seq
- duchenne muscular dystrophy
- high throughput
- high resolution
- single molecule
- genome wide
- copy number
- contrast enhanced
- magnetic resonance imaging
- squamous cell carcinoma
- mass spectrometry
- computed tomography
- magnetic resonance
- high speed
- muscular dystrophy
- end stage renal disease
- neoadjuvant chemotherapy
- newly diagnosed
- peritoneal dialysis
- living cells